The NDUFAF6 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line, engineered for targeted disruption of the NDUFAF6 gene. This product provides a heterogeneous yet functionally validated pool of cells harboring loss-of-function mutations, enabling robust investigation of NDUFAF6-dependent processes. The polyclonal format minimizes clonal selection artifacts and represents a practical model for mitochondrial biology and disease research.
The Raji host cell line is an EBV-positive, suspension-grown lymphoblastoid line originating from a Burkitt lymphoma patient. Raji cells display an immortalized B-cell phenotype with high proliferation rates and stable culture characteristics, making them a widely adopted host in immunology and cancer studies. Their suspension growth facilitates scalable handling, while their transformed metabolic profile offers a relevant background for exploring mitochondrial function in B-cell malignancies.
NDUFAF6 functions as an assembly factor for mitochondrial complex I (NADH:ubiquinone oxidoreductase), essential for the biogenesis of the oxidative phosphorylation machinery. Its expression is regulated by transcription factors including NRF1, GABPA, PPARGC1A, and HIF1A, and it operates within a network of interacting partners such as NDUFAF5, NDUFAF7, NDUFAF1, and TIMMDC1 to facilitate membrane arm assembly. Through these interactions, NDUFAF6 ensures correct integration of core subunits like NDUFS1, NDUFV1, and NDUFS3, and cooperates with ACAD9 and ECSIT in the assembly pathway. Disruption of NDUFAF6 impairs complex I enzyme activity, leading to decreased ATP synthesis, altered mitochondrial membrane potential, and elevated ROS production, ultimately compromising cellular respiration.
In Raji B lymphocytes, NDUFAF6 knockout enables dissection of mitochondrial contributions to lymphoma metabolism. Since Raji cells exhibit a dual dependency on glycolysis and oxidative phosphorylation, loss of complex I assembly may induce a metabolic shift toward glycolysis, akin to the Warburg effect observed in many cancers. This model allows examination of how mitochondrial dysfunction influences B-cell proliferation, survival, and sensitivity to chemotherapeutic agents, while the EBV-positive status provides additional context for studying virus?Cmitochondria interactions and oncogenic stress responses.
Typical applications of this polyclonal knockout model encompass mechanistic studies of mitochondrial complex I deficiency, metabolic reprogramming in cancer, and screening of compounds targeting mitochondrial pathways. Compatible analytical techniques include Western blotting for complex I subunit expression, spectrophotometric complex I enzyme assays, Seahorse metabolic flux analysis to measure oxygen consumption rate, ROS detection with fluorescent probes, and NAD+/NADH ratio quantification. For further details or customized support, please contact Ascent Research.
